Midolam5 mg/ml

Midolam is a short-acting benzodiazepine used mainly in hospital and clinical settings, under the supervision of trained healthcare professionals.

Established / FDA-approved uses

• Sedation, anxiolysis, and amnesia before or during diagnostic or therapeutic procedures (e.g. endoscopy, bronchoscopy, cardiac catheterization)
• Premedication and induction of general anesthesia, and as a component of balanced anesthesia
• Continuous sedation of intubated, mechanically ventilated patients in intensive care

Guideline-supported use

• First-line treatment of acute seizures and status epilepticus, particularly by the intramuscular, buccal, or intranasal route when intravenous access is not immediately available

Other approved use (market-specific, short-term only)

• Short-term treatment of severe insomnia (oral tablet, in markets where this indication is approved), limited to a few days due to the risk of tolerance and dependence

All uses of Midolam require administration or prescribing by a qualified healthcare professional; it is not intended for unsupervised self-medication.

Each formulation contains Midazolam (as hydrochloride or maleate salt) as the active ingredient. Midazolam is available in various markets as an injectable solution for IM/IV use (in strengths such as 1 mg/mL, 5 mg/mL), oral syrup, tablets, and nasal spray, depending on local registration.

Midolam is a short-acting benzodiazepine derivative with sedative, hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant properties, along with a strong amnestic effect. It has a rapid onset of action and a relatively short duration of effect compared with other benzodiazepines, which makes it useful for procedural sedation and anesthesia induction.

Midolam is a controlled substance in most jurisdictions and is typically administered by, or under the direct supervision of, healthcare professionals trained in airway management, with resuscitation equipment readily available, due to its risk of causing respiratory depression.

Midazolam acts by binding to a specific site on the GABA-A receptor complex in the central nervous system, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA). This increases the frequency of chloride-channel opening, causing neuronal hyperpolarization and generalized CNS depression.

This mechanism produces sedative, hypnotic, anxiolytic, anticonvulsant, amnestic, and muscle-relaxant effects.

Pharmacokinetics

• Onset: Rapid — within 1-5 minutes intravenously; 10-20 minutes intramuscularly
• Metabolism: Extensively hepatic, primarily via CYP3A4, to the active metabolite 1-hydroxymidazolam
• Elimination half-life: Approximately 1.5-2.5 hours in healthy adults; prolonged in elderly, obese, and hepatic- or renal-impaired patients
• Excretion: Primarily renal, as glucuronide conjugates

Midolam may be given by the intravenous, intramuscular, oral, buccal, intranasal, or (in some settings) rectal route, depending on formulation and indication.

• Intravenous doses should be injected slowly (over at least 2 minutes) with adequate time to assess effect before further dosing.
• Parenteral Midolam should only be given in a setting with continuous monitoring of oxygenation, ventilation, and circulation, and with resuscitation equipment and personnel trained in airway management immediately available.
• Oral and other outpatient forms should be taken exactly as prescribed; do not adjust the dose or route without medical advice.
• Midolam should not be self-administered outside a supervised clinical context for sedation/anesthesia indications.

Midolam has clinically important interactions that increase the risk of excessive sedation and respiratory depression:

• Opioids and other CNS depressants (e.g. other sedatives, alcohol, general anesthetics): concomitant use with Midolam may result in profound sedation, respiratory depression, coma, and death (see boxed warning under Precautions).
• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, voriconazole, ritonavir and other protease inhibitors, clarithromycin): can markedly increase Midolam blood levels and prolong sedation and respiratory depression; concurrent use with oral Midolam should generally be avoided.
• Strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin, St. John's Wort): may reduce the effectiveness of Midolam.
• Grapefruit juice: may increase oral bioavailability of Midolam and should be avoided.

Adverse effects of Midolam vary by route and dose. The most serious risk, respiratory depression and apnea (see Precautions and Warnings), is more common with intravenous administration, higher doses, or concomitant CNS depressants.

Common

• Drowsiness, sedation, and fatigue
• Headache
• Hiccups, nausea, or vomiting
• Injection-site pain or local reaction
• Amnesia (anterograde memory loss), which is often an intended effect for procedural sedation

Less common / serious

• Decreased respiratory rate, hypoxia, apnea
• Hypotension, bradycardia
• Paradoxical reactions: agitation, involuntary movements, combativeness (more frequent in children and the elderly)
• Laryngospasm or bronchospasm
• Allergic reactions

Pregnancy: Midolam crosses the placenta. Benzodiazepines have been associated with a risk of congenital abnormalities when used in early pregnancy, and with neonatal respiratory depression or withdrawal/floppy-infant syndrome when used near delivery. Midolam should be avoided during pregnancy unless there is no safer alternative and the potential benefit clearly justifies the potential risk to the fetus; use only under the direction of a physician.

Lactation: Midolam is excreted in breast milk. Breastfeeding is generally not recommended for a period after receiving Midolam, and a physician should advise on the appropriate interval before resuming breastfeeding.

Boxed warning: risk of respiratory depression

Midolam carries a risk of serious, life-threatening respiratory depression and arrest, especially when used for sedation in non-critical-care or non-monitored settings, or when combined with opioids or other CNS depressants. Midolam should be administered only by, or under the direct supervision of, personnel trained in the recognition and management of airway obstruction and ventilatory depression, with resuscitation equipment and age-appropriate reversal agents readily available. Doses must be individualized and titrated slowly, particularly in the elderly, debilitated, or critically ill.

Other important precautions

• Elderly, debilitated, and hepatically or renally impaired patients require lower doses and closer monitoring due to prolonged effect.
• Prolonged use of Midolam can lead to physical dependence and tolerance; abrupt discontinuation after extended use may precipitate a withdrawal syndrome (which can include seizures) and should be avoided — dose should be tapered under medical supervision.
• Use with caution in patients with chronic respiratory disease (e.g. COPD) or sleep apnea, in whom respiratory depression may be more pronounced.
• Midolam is not intended for unsupervised self-administration; follow your physician's instructions exactly and do not alter the dose or route.

Overdose of Midolam may cause excessive drowsiness, confusion, impaired coordination, slowed or stopped breathing (respiratory depression/apnea), very low blood pressure, and coma; the risk is greater when combined with alcohol, opioids, or other CNS depressants.

Suspected overdose is a medical emergency: seek immediate medical attention or contact emergency services/poison control right away. Treatment is generally supportive, with attention to airway, breathing, and circulation in a monitored setting; a specific benzodiazepine antagonist may be used by medical personnel in certain situations, but this carries its own risks and must only be given by trained professionals. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep out of reach of children. Injection formulations should be inspected visually for particulate matter or discoloration before use.

• Elderly: More sensitive to the sedative and respiratory-depressant effects of Midolam; lower doses and slower titration are required.
• Hepatic impairment: Clearance of Midolam is reduced, prolonging sedation and increasing the risk of respiratory depression; dose reduction and monitoring are needed.
• Renal impairment: The active metabolite of Midolam can accumulate, especially in renal failure, prolonging effects; use with caution and reduced dosing.
• Obesity: Dosing of Midolam is generally based on ideal or adjusted body weight, since it distributes into fat tissue.
• Pediatric patients: See Pediatric Uses below.
• Critically ill / ICU patients: Prolonged continuous infusion increases risk of accumulation, tolerance, and withdrawal on discontinuation; daily sedation interruption and monitoring are recommended per institutional protocol.

For procedural sedation and anesthesia induction, Midolam is typically given as a single dose or brief series of doses under direct supervision. For continuous ICU sedation, the shortest effective duration is recommended, with regular reassessment, since prolonged infusion increases the risk of tolerance, accumulation, and withdrawal on stopping. Where used short-term for insomnia, treatment with Midolam should generally not exceed a few days to a couple of weeks, due to the risk of tolerance and dependence with longer use. Any change in duration should be decided by the treating physician.

Benzodiazepines

D

Midolam is used in pediatric patients for premedication and sedation before procedures or anesthesia, and for the emergency treatment of acute seizures/status epilepticus, using weight-based dosing appropriate to the specific route and formulation.

Dosing must be individualized by a clinician experienced in pediatric sedation and airway management, as children — especially those under 6 years — may require proportionally higher mg/kg doses and are also at increased risk of paradoxical reactions and respiratory depression. Safety and efficacy of some routes and formulations of Midolam have not been established in neonates and premature infants, and extra caution (including attention to excipients such as benzyl alcohol in some injectable products) is required in this age group. Midolam should only be given to children under direct medical supervision.